A quieter week for exits and a louder one for enforcement: a $541.5 million Medicare Advantage upcoding settlement, a court telling Elevance it is likely right on star ratings but too late for relief, and an appeals court leaving Medicare drug price negotiation intact.
National headlines
1. The Villages Health settles Medicare Advantage upcoding allegations for $541.5 million
What happened: The Villages Health, a Central Florida primary and specialty care provider serving about 55,000 patients, agreed to pay $541.5 million to resolve Justice Department allegations that it submitted unsupported diagnosis codes for Medicare Advantage patients from 2020 through 2024, including codes added months or years after visits. By 2024, about half of its patient codes lacked medical record support. The insurers paid on those codes included UnitedHealthcare and Humana. The provider self-disclosed, went through bankruptcy in 2025 and is now owned by Humana's CenterWell. A day earlier, Monogram Health agreed to pay $2.4 million over similar allegations involving Cigna and Humana members.
Why it matters: The coding happened at the provider, but the risk-adjusted revenue landed at the plan. As DOJ works through provider-level cases, the plans that paid on those codes face refund exposure, audit attention and reputational spillover, and the case is a live example of how a delegated or value-based arrangement can import coding risk into a plan's book.
Strategic implication: Treat retrospective chart review and provider-submitted diagnosis additions as a compliance priority before RADV and DOJ make it one. Specifically, look for late-added codes and for providers whose coding intensity moved sharply year over year. For strategy teams, factor coding normalization into any growth plan that depends on risk-bearing provider partners.
Becker's reported the settlement was approved by the bankruptcy court on August 25. The Monogram settlement was reported August 26.
On this site: Policy impact
2. Court denies Elevance's emergency star ratings request but says it is likely to win on the merits
What happened: On August 27, a federal judge rejected Elevance's request for an emergency recalculation of its 2026 Medicare Advantage star ratings, finding the company waited too long after the October 2025 ratings release and did not show irreparable harm. Elevance argues it was treated unfairly after a May ruling for Clover Health removed 20 measures from Clover's rating and lifted it from 3.5 to 4.5 stars; the recalculation CMS then applied to other plans left Elevance's five contracts unchanged, which it says costs about $115 million in 2027 quality bonus payments. The judge found Elevance substantially likely to succeed on its claims about unlawful measures.
Why it matters: The ruling separates two questions every plan now faces: whether specific star measures are lawful, and whether a plan can get relief in time to matter for a payment year. The answer to the second is increasingly no unless a challenge is filed quickly. With CMS appealing the Clover decision, the measure set itself is unsettled heading into the next ratings release.
Strategic implication: Stars and legal teams should agree now on how quickly the organization would challenge a ratings outcome, and on which measures are exposed if the Clover reasoning holds on appeal. Competitive analysis should flag contracts whose bonus status could change through litigation, not only through performance.
Activity date is the court's decision; Becker's published August 28.
On this site: Star movement
3. Henry Ford's Health Alliance Plan grows Medicare Advantage membership 46%
What happened: Henry Ford Health's Health Alliance Plan reported 132,566 Medicare Advantage members as of June 30, 2026, up 45.8% from 90,935 a year earlier. Premium revenue rose 26.1% to $1.7 billion for the first half, while provider expenses rose 34.4% to $1 billion, driven mainly by the new Medicare Advantage members, with an 86.9% medical loss ratio. Medicaid and individual membership fell over the same period.
Why it matters: This is the other side of the national retrenchment story: a provider-sponsored plan in Michigan adding more than 41,000 Medicare Advantage members in a year. It follows a week in which Providence Health Plan closed after failing to sell its Medicare Advantage book, so the provider-sponsored model is producing both the fastest growers and the clearest failures.
Strategic implication: When mapping 2027 competition, do not assume displaced members go to the next-largest national carrier. Regional and provider-sponsored plans with local networks are absorbing volume. Track their cost trend as closely as their growth: expenses growing faster than premium is the early signal of a benefit or footprint reset a year later.
On this site: Compare markets · Carrier footprint
4. Fifth Circuit upholds Medicare drug price negotiation
What happened: The U.S. Court of Appeals for the Fifth Circuit affirmed a lower court ruling against PhRMA and co-plaintiffs challenging the Inflation Reduction Act's drug price negotiation program. Judge Leslie Southwick wrote that manufacturers lack a protected interest in selling to Medicare beneficiaries at a preferred price because participation in Medicare and Medicaid is voluntary. PhRMA said it was reviewing the decision and its options.
Why it matters: With industry challenges now rejected by the Second, Third, Fifth and D.C. Circuits, the negotiated prices already in effect for 10 drugs in 2026, and those for 15 more Part D drugs on January 1, 2027, look settled for planning purposes.
Strategic implication: Part D and MA-PD pricing teams should treat negotiated prices as a fixed input rather than a litigation risk. The practical questions shift to formulary placement, pharmacy reimbursement for negotiated drugs, and how lower list prices change rebate economics and member out-of-pocket exposure in 2027 plan designs.
Fierce Pharma, published August 27, reports the ruling came on Wednesday, August 26. The circuit list comes from Patients For Affordable Drugs.
On this site: Negotiated drug prices
5. Medi-Cal loses 730,000 enrollees, with tighter asset limits for older adults still ahead
What happened: Medi-Cal enrollment fell by about 730,000, roughly 5%, between June 2025 and March 2026, to just over 14 million, with most of the drop in the first quarter of 2026, according to a California Health Care Foundation analysis of state data. The analysis notes California will lower Medi-Cal asset limits for older adults and people with disabilities in July 2027.
Why it matters: California is the largest Medicaid market in the country, and asset limits for older adults and people with disabilities apply directly to the population that qualifies for dual eligibility. Fewer full duals means a smaller eligible pool for D-SNP and integrated plans, and more members moving between D-SNP and general Medicare Advantage.
Strategic implication: D-SNP teams in California should model enrollment under the July 2027 asset limit change now, including how many current members may lose Medicaid eligibility and what the retention path into a non-D-SNP product looks like. Outside California, treat state eligibility rules as a leading indicator for dual-eligible density.
The prior issue covered Medi-Cal plans preparing for the asset limit change. What is new this week is the enrollment decline data.
On this site: Dual-eligible density · D-SNP deployment
6. Study finds lead generators steering shoppers away from ACA plans
What happened: Georgetown University researchers posing as two West Virginia consumers fielded 20 sales calls over three days in May 2026. Every website in their search results was a lead generator rather than an official marketplace, and 17 of 20 sales representatives steered them away from ACA plans, including one profile that qualified for a $0 bronze plan. Representatives described ACA coverage as the public market and alternatives as the private market.
Why it matters: This is an individual-market study, but the mechanics are the same lead-generation and call-center channel that feeds Medicare Advantage enrollment, and the researchers describe enforcement against these practices as whack-a-mole. As carriers cut commissions and shoppers lean more on search, more Medicare volume runs through intermediaries whose incentives do not match the plan's.
Strategic implication: Audit where your Medicare leads originate and what scripts downstream agents use before AEP opens. CMS holds plans responsible for overseeing third-party marketing done on their behalf, and a misleading-steering story in Medicare would land on the carrier brand.
On this site: Marketing intelligence
Compiled September 28, 2026. Covers material national developments from August 24-30, 2026, with clearly labeled exceptions where background is needed to read a development inside the window.
Provided for general informational and educational purposes only. It is not legal, financial, insurance or regulatory advice and should not be relied on as such; consult qualified professionals before acting on anything here. © 2026 medicareinsights.org.